The University Of Texas MD Anderson Cancer Center
Childhood cancer survivor turned pediatric oncologist aims to ‘give hope’ to patients
Richard Gorlick, MD, received this year’s ASCO Pediatric Oncology Award, which recognizes an individual who made outstanding contributions to the field.
Zanidatamab exhibits ‘promising’ efficacy in advanced HER2-positive biliary tract cancer
CHICAGO — Zanidatamab exhibited durable antitumor activity among patients with previously treated advanced HER2-amplified biliary tract cancer, according to results of the phase 2B HERIZON-BTC-01 study presented at ASCO Annual Meeting.
Findings highlight ‘desperate need’ to improve end-of-life cancer treatment
Oncologic treatment of adults with various metastatic or advanced solid tumors may not improve OS and could be detrimental to quality of life, according to findings published in JAMA Oncology.
FDA approves Anktiva for certain patients with bladder cancer
The FDA approved nogapendekin alfa inbakicept-pmln plus Bacillus Calmette-Guerin for the treatment of certain patients with bladder cancer, according to a press release from the manufacturer.
Next-generation PARP inhibitor shows clinical benefit in certain patients with breast cancer
Saruparib conferred clinically impactful treatment outcomes among adults with breast cancer who harbor certain genetic mutations, according to data presented at American Association for Cancer Research Annual Meeting.
Neoadjuvant immunotherapy may improve sarcoma outcomes
A phase 2 trial conducted by researchers at The University of Texas MD Anderson Cancer Center demonstrated the safety and potential efficacy of neoadjuvant immunotherapy for patients with soft tissue sarcoma.
Futibatinib-fulvestrant combination active in FGFR1-amplified advanced breast cancer
SAN ANTONIO — Futibatinib plus fulvestrant exhibited antitumor activity among certain patients with locally advanced or metastatic breast cancer with fibroblast growth factor receptor 1 amplification, according to study results.
‘Off-the-shelf’ cell therapy shows ‘very encouraging’ results for B-cell malignancies
Nearly one-half of adults with relapsed or refractory CD19-positive B-cell malignancies responded to treatment with a novel cord blood-derived natural killer cell therapy expressing a chimeric antigen receptor, study results showed.
Cervical cancer incidence, mortality rises sharply in America's poorest counties
A study led by researchers at The University of Texas MD Anderson Cancer Center revealed an alarming increase in cervical cancer incidence and mortality among women living in America’s lowest-income counties.
‘Disappointing’ results question the utility of liquid biopsy-guided cancer treatment
Circulating tumor DNA did not successfully predict whether patients with resected stage II colon cancer would benefit from adjuvant chemotherapy, according to findings presented at ASCO Gastrointestinal Cancers Symposium.